FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

Submitted by admin on June 6, 2024 - 9:11pm

Source:

Reuters

News Tags:

Eli Lilly

FDA

Alzheimer's disease

donanemab

Headline:

FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

snippet:

An FDA analysis of trial data for Eli Lilly's (LLY.N), experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.

Search form

You are here

FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

FDA staff raise no major concerns about Eli Lilly Alzheimer's drug